Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––– SCHEDULE 14A INFORMATION _____________________________________ Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. 1)

| Filed by the Registrant                    |     | ☒ |
| Filed by a Party other than the Registrant |     | ☐ |

Check the appropriate box:

| ☒ |     | Preliminary Proxy Statement                                                         |
| ☐ |     | Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |     | Definitive Proxy Statement                                                          |
| ☐ |     | Definitive Additional Materials                                                     |
| ☐ |     | Soliciting Material Pursuant to §240.14a-12                                         |

CERO THERAPEUTICS HOLDINGS, INC. (Name of Registrant as Specified in its Charter) ______________________________________________________________
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required.                                                                                     |
| ☐ |     | Fee paid previously with preliminary materials.                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

Explanatory Note This Amendment No. 1 to Schedule 14A is being filed by CERo Therapeutics Holdings, Inc. (the “Company”) to revise the Company’s Preliminary Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 25, 2025, by (i) adding the range of the proposed reverse stock split to Proposal No. 1; and (ii) supplementing Proposal No. 3 with discussion of the potential dilution resulting from the application of certain adjustments to the conversion price of the Company’s Series D convertible preferred stock, par value $0.0001 p er s hare, on the Company’s stockholders.

PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION CERO THERAPEUTICS HOLDINGS, INC. 201 Haskins Way, Suite 230
South San Francisco, CA 94080 2025